Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Steward

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|March 21, 2002
Angiogenesis as a biomarker and target in cancer chemopreventionR A Sharma, A L Harris, A G Dalgleish, et al.
Investigational New Drugs|January 1, 1995
Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials GroupG Goss, A Muldal, R Lohmann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?G Garcea, T D Lloyd, A Gescher, et al.
The British Journal of Surgery|October 13, 2007
Assessment of a patient consultation questionnaire-based scoring system for stratification of outpatient risk of colorectal cancerS Rai, M Ballal, W M Thomas, et al.
British Journal of Cancer|January 11, 2007
Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesisR D Verschoyle, P Greaves, H Cai, et al.
British Journal of Cancer|May 4, 2006
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imagingB Morgan, J F Utting, A Higginson, et al.
Pathology Oncology Research : POR|August 11, 2000
Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?G Cox, R A Walker, S Muller, et al.
British Journal of Cancer|January 1, 1989
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity studyW P Steward, J H Scarffe, R Austin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Ifosfamide by bolus as treatment for advanced non-small cell lung cancerN Thatcher, H Anderson, D B Smith, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 22, 2001
Involving patients in treatment decisions: can we learn from clinical trials?R A Sharma, R P Symonds, K J O'Byrne, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|March 21, 2002
Angiogenesis as a biomarker and target in cancer chemopreventionR A Sharma, A L Harris, A G Dalgleish, et al.
Investigational New Drugs|January 1, 1995
Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials GroupG Goss, A Muldal, R Lohmann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?G Garcea, T D Lloyd, A Gescher, et al.
The British Journal of Surgery|October 13, 2007
Assessment of a patient consultation questionnaire-based scoring system for stratification of outpatient risk of colorectal cancerS Rai, M Ballal, W M Thomas, et al.
British Journal of Cancer|January 11, 2007
Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesisR D Verschoyle, P Greaves, H Cai, et al.
British Journal of Cancer|May 4, 2006
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imagingB Morgan, J F Utting, A Higginson, et al.
Pathology Oncology Research : POR|August 11, 2000
Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?G Cox, R A Walker, S Muller, et al.
British Journal of Cancer|January 1, 1989
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity studyW P Steward, J H Scarffe, R Austin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Ifosfamide by bolus as treatment for advanced non-small cell lung cancerN Thatcher, H Anderson, D B Smith, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 22, 2001
Involving patients in treatment decisions: can we learn from clinical trials?R A Sharma, R P Symonds, K J O'Byrne, et al.
Pageof 13